SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia
Status:
Withdrawn
Trial end date:
2014-02-24
Target enrollment:
Participant gender:
Summary
To assess the safety and efficacy of SPD489 low-dose and high-dose treatment groups to
placebo when given as adjunctive therapy to antipsychotic medication in clinically stable
adults with persistent predominant negative symptoms of schizophrenia.